User profiles for "author:Claudia Carella"

Claudia Carella

Technical Co-worker Italian National Institute of Health
Verified email at iss.it
Cited by 416

Donation after circulatory death today: an updated overview of the European landscape

M Lomero, D Gardiner, E Coll… - Transplant …, 2020 - Wiley Online Library
Donation after circulatory death (DCD) has become an accepted practice in many countries
and remains a focus of intense interest in the transplant community. The present study is …

[HTML][HTML] SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand

R Palmirotta, C Carella, E Silvestris, M Cives… - Oncotarget, 2018 - ncbi.nlm.nih.gov
In the “precision medicine” era, chemotherapy still remains the backbone for the treatment of
many cancers, but no affordable predictors of response to the chemodrugs are available in …

Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: real world data and post progression outcome

SC Cecere, G Giannone, V Salutari, L Arenare… - Gynecologic …, 2020 - Elsevier
Objectives Olaparib is approved as maintenance therapy in patients with BRCA mutated
platinum sensitive (PS) recurrent ovarian cancer (OC) after response to last platinum based …

Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

BA Maiorano, M Di Maio, L Cerbone… - JAMA Network …, 2024 - jamanetwork.com
Importance Immune checkpoint inhibitors (ICIs) have broadened the metastatic urothelial
carcinoma (mUC) therapeutic scenario. The association of programmed death ligand 1 (PD …

[HTML][HTML] The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal …

SE Rebuzzi, A Signori, M Stellato, D Santini… - Frontiers in …, 2022 - frontiersin.org
Background: Treatment choice for metastatic renal cell carcinoma (mRCC) patients is still
based on baseline clinical and laboratory factors. Methods: By a pre-specified analysis of …

Addition of niraparib to best supportive care as maintenance treatment in patients with advanced urothelial carcinoma whose disease did not progress after first-line …

F Vignani, R Tambaro, U De Giorgi, P Giannatempo… - European Urology, 2023 - Elsevier
Background Platinum-based chemotherapy (PBCT) is the standard first-line treatment for
advanced urothelial carcinoma (UC). Potential cross-sensitivity can be hypothesized …

Standardization of CTC AR‐V7 PCR assay and evaluation of its role in castration resistant prostate cancer progression

S Tommasi, B Pilato, C Carella, A Lasorella… - The …, 2019 - Wiley Online Library
Background Castration resistant prostate cancer (CRPC) represents the most aggressive
status of this neoplastic disease, also characterized by the absence of biomarkers predictive …

[HTML][HTML] Pembrolizumab plus axitinib for metastatic papillary and chromophobe renal cell carcinoma: NEMESIA (non clear MEtaStatic renal cell carcinoma …

M Stellato, S Buti, M Maruzzo, M Bersanelli… - International Journal of …, 2023 - mdpi.com
Non-clear cell renal cell carcinoma (nccRCC) represents a heterogeneous histological
group which is 20–25% of those with renal cell carcinoma (RCC). Patients with nccRCC …

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro …

G Roviello, E Gambale, R Giorgione, D Santini… - Cancer …, 2022 - Wiley Online Library
Background Nivolumab and cabozantinib are currently approved agents in metastatic renal
cell carcinoma (mRCC) but there are no data available for patients progressing to both …

[HTML][HTML] Ki67 as a predictor of response to PARP inhibitors in platinum sensitive BRCA wild type ovarian cancer: the MITO 37 retrospective study

V Tuninetti, E Ghisoni, S Pignata, E Picardo… - Cancers, 2023 - mdpi.com
Simple Summary Low cost, reliable predictors of benefit from PARP inhibitors (PARPi) are
missing for relapsed BRCA wild-type (WT) ovarian cancer (OC). MITO 37 is a multicenter …